Abstract
Tumor necrosis factor-alpha (TNF-alpha) inhibitors have been used in the treatment of psoriasis, which is associated with the insulin resistance syndrome. The purpose of this study was to determine the effect of etanercept, a TNF-alpha inhibitor, on insulin secretion and insulin sensitivity in psoriatic patients with high risk factors to develop type 2 diabetes mellitus. Randomized double blind clinical trial with 2 weeks of follow-up. The allocation was done by simple randomization. The investigation was performed in 12 psoriatic patients with indication of systemic treatment and 2 or more risk factors for type 2 diabetes mellitus. Patients with infections, topical corticosteroids or salicylic acid ointments for 6 weeks before the study, diabetes, acromegaly, cancer and other systemic diseases were excluded. All subjects gave written informed consent to participate in the study and the protocol was approved by the hospital-based Ethical Committee. Etanercept was injected in a subcutaneous dose of 25 mg in 1 ml twice by week for 2 weeks or 1 ml of saline solution as placebo. Insulin secretion was estimated with the formula for the homeostasis model analysis β-cell function index and insulin sensitivity was assessed using the euglycemic-hyperinsulinemic clamp technique. There was no significant difference in insulin secretion and insulin sensitivity with etanercept. Fasting serum insulin levels were decreased in the etanercept group (146 ± 117–111 ± 87 pmol/l, P = 0.04). Etanercept did not modify insulin secretion and insulin sensitivity in psoriatic patients with risk factors for type 2 diabetes mellitus.
References
Bloomgarden Z (2003) Inflammation and insulin resistance. Diabetes Care 26:1619–1623
Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B (2002) cFLIP Protein prevents tumor necrosis factor-[alpha]-mediated induction of caspase-8-dependent apoptosis in insulin-secreting [beta]Tc-Tet cells. Diabetes 51:1805–1814
Culy C, Keating G (2002) Etanercept. Drugs 2:2493–2437
DeFronzo RA, Tobin J, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6:E214–E223
Gellfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741
González-Ortiz M, Martínez-Abundis E, Balcázar-Muñoz B, Robles-Cervantes J (2001) Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects. Horm Metab Res 33:250–253
González-Ortiz M, Martínez-Abundis E, Lifshitz A (1998) Insulin sensitivity and sex steroid hormone levels during the menstrual cycle in healthy women with non-insulin-dependent diabetic parents. Gynecol Obstet Invest 46:187–190
Gottlieb A (2001) Psoriasis: immunopathology and immunomodulation. Dermatol Clin 19:649–655
Hotamisligil G, Shargill N, Spiegelman B (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:7–90
Iyer S, Yamauchi P, Lowe N (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118–121
Jeyasseelan L, Rao P (1989) Methods of determining sample sizes in clinical trials. Indian Pediatr 26:115–121
Kormeili T, Lowe N, Yamauchi P (2004) Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies: US experiencies. Br J Dermatol 151:3–15
Korth-Bradley JM, Sue-Rubin A, Hanna RK, Simcoe DK, Lebsack ME (2000) The pharmacokinetics of etanercept in healthy volunteer. Ann Pharmacother 34:161–164
Krueger G, Callis K (2004) Potential of tumor necrosis factor inhibitor in psoriasis and psoriatic arthritis. Arch Dermatol 140:218–225
LaDuca J, Gaspari A (2001) Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19:617–635
Ludwig R, Herzog C, Rostock A, Ochsendorf F, Zollner T, Thaci D, Kaufmann R, Vogl T, Boehncke W (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 56:2761–2627
Miyazaki Y, Pipek R, Mandarino L, DeFronzo R (2003) Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obes 27:88–94
Ofei F, Hurel S, Newkirk J, Sopwith M Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885
Pakala S, Chivetta M, Kelly C, Katz J (1999) In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 189:1053–1062
Paquot N, Castillo M, Lefèbvre P, Scheen A (2000) No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 85:1316–1319
Rask-Madsen C, Domínguez H, Ihlemann N, Hermann T, Køber L, Torp-Pedersen C (2002) Tumor necrosis factor-[alpha] inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilatation in humans. Circulation 108:1815–1821
Spranger-Joachim K, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 52:812–817
von Eckardstein A, Schulte H, Assmann G (2000) Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 85:3101–3108
Weir G, Laybutt D, Kaneto H, Bonner-Weir S, Sharma A (2001) Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 50:S154–S159
Winkler G, Lakatos P, Salamon F, Speer G, Baranyi E, Melczer Z, Karoly C (1999) Response to Fernandez-Real et al. Contribution of tumor necrosis factor-alpha in insulin resistance in patients with android type obesity. Diabetes Care 22:870
Yoshitaka S, Hiroaki D, Shuji M, Masayuki I, Satoshi T, Tomohiko T, Toshihiko I (2004) Infliximab (anti-tnf alpha antibody) improved insulin resistance in rheumatoid arthritis patients. Diabetes 53:A160–A161
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martínez-Abundis, E., Reynoso-von Drateln, C., Hernández-Salazar, E. et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 299, 461–465 (2007). https://doi.org/10.1007/s00403-007-0784-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-007-0784-3